A 59-year-old female with an unresectable, large pancreatic tumor (10.0 Â 8.0 cm 2 on CT scan) underwent nonmyeloablative allogeneic peripheral-blood stem-cell transplantation from her HLA-identical sibling. Pronounced tumor regression and relief from pain without acute graft-versus-host disease (GVHD) were observed following transplantation. The patient is surviving (more than 300 days) after transplantation, with extensive chronic GVHD, and has tumor regression with an 80% reduction in tumor size. The observed clinical course may suggest a graft-versus-tumor effect on the pancreatic tumor following allogeneic stem-cell transplantation. Bone Marrow Transplantation (2003) 31, 943-945. doi:10.1038/sj.bmt.1703932 Keywords: non-myeloablative allogeneic stem cell transplantation; graft-versus-tumor effect; pancreatic tumor Allogeneic stem-cell transplantation (ASCT) has been proven to have potent antitumor effects not only in patients with hematologic malignancies, 1 but also in those with solid tumors.
Summary:
A 59-year-old female with an unresectable, large pancreatic tumor (10.0 Â 8.0 cm 2 on CT scan) underwent nonmyeloablative allogeneic peripheral-blood stem-cell transplantation from her HLA-identical sibling. Pronounced tumor regression and relief from pain without acute graft-versus-host disease (GVHD) were observed following transplantation. The patient is surviving (more than 300 days) after transplantation, with extensive chronic GVHD, and has tumor regression with an 80% reduction in tumor size. The observed clinical course may suggest a graft-versus-tumor effect on the pancreatic tumor following allogeneic stem-cell transplantation. Bone Marrow Transplantation (2003) 31, 943-945. doi:10.1038/sj.bmt.1703932 Keywords: non-myeloablative allogeneic stem cell transplantation; graft-versus-tumor effect; pancreatic tumor Allogeneic stem-cell transplantation (ASCT) has been proven to have potent antitumor effects not only in patients with hematologic malignancies, 1 but also in those with solid tumors. 2, 3 Regarding nonmyeloablative allogeneic peripheral-blood stem-cell transplantation for solid malignancies, Childs et al 4, 5 reported successful treatment of metastatic renal-cell carcinoma and demonstrated clinically the existence of a graft-versus-tumor (GVT) effect. A GVT effect was also reported in a patient with colonic cancer; 6 however, there have been no reports of GVT effects in patients with pancreatic tumors, which are notorious for having an extremely poor prognosis. 7 Radiation therapy and cytotoxic chemotherapy have thus far been unable to significantly prolong survival with pancreatic tumors. Therefore, a novel therapeutic modality has been sought. We describe continuous regression of a large pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Case report and results
A 59-year-old woman consulted her local doctor because of increasing severe upper abdominal pain. Physical examination revealed a hard mass, greater than fist sized, in her upper central abdomen, and she was referred to our hospital. She had lost 5 kg body weight during the previous 3 months. No jaundice was noted. Abdominal CT scans revealed a heterogeneously enhanced 10.0 Â 8.0 cm 2 tumor, with an irregular, low-density area suggestive of central necrosis (Figure 1a) . No liver or other distant metastases were noted. Fine-needle aspiration biopsy confirmed adenocarcinoma ( Figure 2) . CEA, CA19-9, and LDH were within normal limits. In all, 20 mg of morphine relieved the patient's severe pain. Based on the above findings, the patient was diagnosed as having a pancreatic tumor. Although this pancreatic tumor was not a typical pancreatic duct cell carcinoma, it was ascertained that the tumor arose from the pancreatic tissue, as indicated by the CT scan and angiography. Assessment of tumor size, and the major vascular invasion by the tumor, deemed it unresectable.
Knowing the poor survival rates after conventional treatment for advanced pancreatic tumor, the patient indicated an interest in undergoing nonmyeloablative ASCT. Full informed consent was obtained in writing. The patient received a protocol approved by the institutional ethics committee 1 month after diagnosis. Pretransplant conditioning consisted of cyclophosphamide, 60 mg/ kg administered intravenously on days À7 and À6, and fludarabine, 25 mg/m 2 administered intravenously from days À5 to À1. Cyclosporin was started on day À2. The patient's HLA-identical sister was given granulocytecolony-stimulating factor (G-CSF) 10 mg/kg subcutaneously daily for 5 days, and mobilized peripheral-blood stem cells were collected by leukapheresis on the fifth and sixth day of G-CSF administration. On day 0 and +1, a total of 6.01 Â 10 6 CD34 þ donor cells/kg were transfused into the patient. Successful engraftment was achieved on day +6. Complete T-cell chimerism and mixed myeloid chimerism were demonstrated on day +7 by polymerasechain-reaction assay of the microsatellite regions. Her posttransplant course was uneventful, and proceeded without symptoms of acute graft-versus-host disease (GVHD). Cyclosporin administration was tapered and discontinued on day +100. The patient's abdominal pain rapidly disappeared within 2 weeks after ASCT, and morphine was successfully discontinued. In addition, the palpable upper abdominal tumor disappeared within 3 weeks. Abdominal CT scans showed an impressive reduction in the post-therapy pancreatic tumor diameter, which dropped from 10.0 to 6.5 cm in diameter (representative of a 60% reduction) on day +30 (Figure 1b) , and to 4.5 cm (representative of a 80% reduction) on day +180 (Figure 1c) . The patient developed extensive chronic GVHD of the skin on day +120 and was given corticosteroid ointment in the outpatient clinic. Complete myeloid chimerism was observed, at almost the same time. Cyclosporin treatment was started again because of the progression of the chronic GVHD of the liver on day +190. When the GVHD had improved, the pancreatic tumor increased in size slightly by day +220. As soon as the cyclosporin was stopped, the tumor again regressed. The patient is surviving in good condition, more than 300 days after transplantation.
We report the marked regression of a large pancreatic tumor following nonmyeloablative allogeneic peripheralblood stem-cell transplantation. There have been no reports of efficacy against pancreatic tumors of the chemotherapeutic agents used in our conditioning regimen. Moreover, complete T-cell chimerism had been achieved at the beginning of the tumor regression, and the tumor had been continuously decreasing in size for more than 180 days after ASCT, with extensive chronic GVHD. The growth of the tumor after restarting cyclosporin, and tumor regression after discontinuation of the cyclosporin might suggest the existence of a GVT effect. Therefore, it is reasonable to consider that the regression following the ASCT can be attributed to a GVT effect on the pancreatic tumor. Nonmyeloablative allogeneic peripheral-blood stem-cell transplantation may provide a promising novel therapeutic modality for patients with pancreatic tumors, which carry an extremely poor prognosis. Regression of an unresectable pancreatic tumor Y Omuro et al
